AstraZeneca (LON:AZN) received a GBX 8,500 ($111.81) price objective from equities research analysts at Barclays in a note issued to investors on Friday, Borsen Zeitung reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Barclays‘s target price would suggest a potential upside of 15.87% from the stock’s previous close.

Other analysts also recently issued reports about the company. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Friday. Bryan, Garnier & Co reiterated a “buy” rating on shares of AstraZeneca in a research report on Thursday, December 19th. Liberum Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Friday. HSBC reiterated a “reduce” rating and set a GBX 6,235 ($82.02) target price on shares of AstraZeneca in a research report on Wednesday, November 27th. Finally, Credit Suisse Group lifted their target price on AstraZeneca from GBX 8,200 ($107.87) to GBX 8,500 ($111.81) and gave the stock an “outperform” rating in a research report on Thursday, January 16th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of GBX 7,912.14 ($104.08).

Shares of AZN opened at GBX 7,336 ($96.50) on Friday. The company has a market cap of $100.07 billion and a PE ratio of 46.02. The business has a fifty day moving average of GBX 7,668.20 and a 200 day moving average of GBX 7,328.85. AstraZeneca has a 52-week low of GBX 109.51 ($1.44) and a 52-week high of GBX 8,227.88 ($108.23). The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 148.59.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What is Depreciation?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.